Document is current
Any future updates will be listed below
-
Authors
LaPelusa, Michael https://orcid.org/0000-0001-6078-0561
Qiao, Wei
Iorgulescu, Bryan
San Lucas, Francis
Patel, Keyur
Bhamidipati, Deepak
Thomas, Jane Varkey
You, Nancy https://orcid.org/0000-0002-5294-288X
Foo, Wai Chin https://orcid.org/0000-0002-0471-4911
Maru, Dipen https://orcid.org/0000-0002-9134-7709
Thirumurthi, Selvi
Morris, Van https://orcid.org/0000-0002-4911-2252
Kopetz, Scott https://orcid.org/0000-0001-9647-3416
Overman, Michael
Ludford, Kaysia
- License Information
-
More Information
Article History
Received: 17 December 2024
Accepted: 29 April 2025
First Online: 15 May 2025
Competing interests
: Scott Kopetz has ownership interest in Lutris, Frontier Medicines, Navire and is a consultant for Genentech, Merck, Boehringer Ingelheim, Bayer Health, Pfizer, Mirati Therapeutics, Flame Biosciences, Carina Biotech, Frontier Medicines, Replimune, Bristol-Myers Squibb-Medarex, Amgen, Tempus, Harbinger Oncology, Zentalis, AVEO, Tachyon Therapeutics, Agenus, Revolution Medicines, Kestrel Therapeutics, Roche, Arcus Biosciences, AstraZeneca Pharmaceuticals, BeiGene, Clasp Therapeutics, Cytovation, Dewpoint Therapeutics, Marengo Therapeutics, SageMedic, Servier, Sibylla, T-Cypher Bio, XAIRA, AmMax Bio, Ikena, and receives research funding from, Guardant Health, Genentech/Roche, EMD Serono, Amgen, Lilly, Daiichi Sankyo, Pfizer, Boehringer Ingelheim, BridgeBio, Zentalis, BioMed Valley, Johnson & Johnson, BMS, Cardiff, Jazz Pharmaceuticals, Frontier Medicines. Michael Overman is a consultant for Merck, Roche, BMS, Astrazeneca, Janssen, Pfizer, Summit, Nouscom, and Amgen. The other authors have no relevant competing interests to disclose.
